ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
63 announcements
Aurobindo Pharma received final US FDA approval for Tofacitinib Tablets used in treating rheumatoid arthritis. The product will be manufactured by its subsidiary and launched immediately.
Aurobindo Pharma inaugurated TheraNym, its large-scale biologics manufacturing facility in Telangana. MSD has joined as the anchor customer, strengthening the company's global contract manufacturing footprint.
Aurobindo delivered record performance in FY26 with revenues at ₹33,653cr and 20.4% EBITDA margins. Strategy focuses on specialty injectables, biosimilars expansion, and backward integration via Pen-G/6-APA projects.
Aurobindo Pharma subsidiary's Unit-I facility received an 'official action indicated' (OAI) classification from the US FDA. The company maintains there is no financial impact.
Aurobindo Pharma's step-down subsidiary incorporated Arrow Pharma Production SAS in France. The new ₹1.11 Crore entity will expand generic formulation manufacturing operations.
Aurobindo Pharma appointed RPR & Associates and Ernst & Young LLP as secretarial and internal auditors. The board meeting also accepted MRR & Associates' resignation.
Aurobindo Pharma re-appointed Ernst & Young LLP as Internal Auditors for June 2026 to May 2027. The move ensures continuity in internal audit and governance processes.
Aurobindo Pharma appointed M/s. RPR & Associates as Secretarial Auditor for five years following M/s. MRR & Associates' resignation. The transition is due to proprietor health issues.
Aurobindo Pharma reported Q4FY26 revenue of ₹8,853 Cr (+5.6% YoY) and PAT of ₹921 Cr (+2.0% YoY). The firm focuses on biosimilars expansion via CuraTeQ and biologics CDMO through TheraNym.
Aurobindo Pharma reported Q4FY26 revenue of ₹8,853 Crore, a 5.6% YoY increase. Net profit rose 2.0% to ₹921 Crore, supported by strong European business growth.
Aurobindo Pharma Ltd reported revenue from operations of ₹8,853 Cr (+5.6% YoY) and net profit of ₹920.8 Cr (+2.0% YoY) for Q4 FY26.
Aurobindo Pharma reported consolidated annual revenue of ₹33,653.08 Crore and profit after tax of ₹3,502.97 Crore. The results show consistent performance across its global pharmaceutical operations.
Aurobindo Pharma subsidiary CuraTeQ received CDSCO marketing approval for Bevqolva, a bevacizumab biosimilar. The authorisation permits domestic manufacturing and marketing for metastatic colorectal cancer treatment.
High Court of Telangana dismissed a writ petition filed by Aurobindo Pharma promoters against SEBI's ₹6.53 Crore profit disgorgement order. The company reported no financial impact.
Aurobindo Pharma scheduled a board meeting on May 21, 2026, to approve fiscal 2026 financial results. The trading window remains closed until May 23, 2026.
Aurobindo Pharma's Unit-VII in Telangana received an Establishment Inspection Report (EIR) from the US FDA. The facility is classified as Voluntary Action Indicated (VAI), and the inspection is now closed. This follows a January-February 2026 inspection that initially resulted in nine observations.
Dr. Sanjay Chaturvedi has resigned as CEO of Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, effective May 4, 2026. He is leaving to pursue a different opportunity. The company has taken the resignation on record.
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received marketing authorization (NOC) from Health Canada for its Bevacizumab biosimilar, Bevqolva™. This regulatory approval follows earlier UK authorization and commercial launch. The biosimilar, used to treat colorectal and lung cancers, will be available in 100 mg and 400 mg formulations, strengthening Aurobindo's global biosimilar portfolio.
Aurobindo Pharma Limited announced that Mr. N. Ravikiran, Chief Business Officer for Emerging Markets and Senior Management Personnel, completed his tenure effective May 1, 2026. This administrative update follows standard SEBI disclosure requirements regarding changes in senior management.
Aurobindo Pharma Limited announced that Mr. N. Ravi Kiran, Chief Business Officer of Emerging Markets, retired from the company. His retirement is effective from the close of business hours on April 30, 2026.
Aurobindo Pharma Ltd submitted its initial disclosure under the SEBI Large Corporate framework for FY 2026-27. The company reported outstanding borrowings of ₹580.00 Crore as of March 31, 2026, and maintains an IND AA+/Stable credit rating. The filing confirms compliance with debt market borrowing requirements.
Aurobindo Pharma Limited announced a share buyback of up to 5,423,728 equity shares via a tender offer at ₹1,475 per share. The total buyback size is ₹800 Crore. The record date is April 17, 2026, with the offer opening on April 23 and closing on April 29, 2026.
Aurobindo Pharma Limited announced a share buyback via tender offer for up to 5,423,728 shares at ₹1,475 each. The total consideration is capped at ₹800 Crore. The buyback opens on April 23, 2026, and closes on April 29, 2026, with promoters intending to participate.
Aurobindo Pharma Limited has submitted a Letter of Offer for the buyback of up to 54,23,728 equity shares at ₹1,475 per share. The total buyback size is ₹800 Crore via the tender offer route. The offer opens on April 23, 2026, and closes on April 29, 2026, targeting a 0.93% reduction in outstanding shares.
Aurobindo Pharma received USFDA final approval for Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC). The product, bioequivalent to Delsym, has an estimated annual market size of ₹1,283.4 Crore ($138M). Manufacturing will occur at the APL Healthcare Unit-IV facility with a planned launch in Q2FY27.
Aurobindo Pharma received final USFDA approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 g/mL. The product, bioequivalent to Ravicti, targets a US$ 50.2 million (₹466.86 Crore) market. Manufacturing will occur at the company's Unit-III facility with an immediate commercial launch planned to treat urea cycle disorders.
Aurobindo Pharma's subsidiary, TheraNym Biologics, will invest approximately ₹1395.0 Crore (USD 150M) to establish a new large-scale mammalian manufacturing facility ('Unit 2'). This greenfield project expands an existing CMO relationship with Merck Sharpe & Dohme (MSD) and will house 60 KL of bioreactor capacity.
Aurobindo Pharma announced a buyback of up to 54,23,728 equity shares at ₹1,475 per share, totaling ₹800 Crore. The buyback will be conducted on a proportionate basis via the tender offer route for eligible shareholders as of the April 17, 2026 record date.
Aurobindo Pharma received USFDA approval for Dapagliflozin and Metformin Hydrochloride ER Tablets, targeting a US$ 514 Million (₹4,780.2 Crore) market. The product, bioequivalent to AstraZeneca's Xigduo XR, will be manufactured at APL Healthcare's Unit-IV and launched immediately with 180 days of shared exclusivity.
Aurobindo Pharma received USFDA approval for Dapagliflozin Tablets (5 mg and 10 mg), addressing a US$ 10.2 billion market. The product, bioequivalent to Farxiga, will be manufactured at APL Healthcare's Unit-IV and launched immediately with 180 days of shared generic exclusivity.